Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
March 12, 2025
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon to all of you. We appreciate you being with us today; joining us on the call are our President and Chief Executive Officer, Howard Robin, our Chief Research and Development Officer, Dr. Jonathan Zalevsky, our Interim Chief Medical Officer, Dr. Brian Kotzin, and our Chief Financial Officer, Sandra Gardiner. On this call, we plan to share some forward-looking statements regarding our company. These will cover things like how our drug candidates and research programs might work therapeutically, what our development plans are for them going forward, when clinical studies might begin, when clinical data for those candidates could become available, the schedule and strategy for presenting that data in the future, how our collaboration agreements come together and whether they succeed, our financial guidance, and a few other matters concerning where our business is headed. Because these statements look ahead, they come with risks and uncertainties that are hard to foresee, and many of them lie beyond our ability to control. What actually happens could end up looking quite different from what we've said. You can find the key risks and uncertainties laid out in our Form 10Q, submitted on November 8, 2024, which you can access at sec.gov. We're not committing to revise any of these forward-looking statements—whether because of fresh information, later events, or any other reason. A webcast of today's call will be posted on the IR section of Nektar's site, nektar.com. Having said that, I'd like to pass things along to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveThanks, Vivian. I appreciate everyone being here today. For Nektar, 2024 has been a year of solid progress, and I feel a great deal of pride in how our team delivered against key clinical development milestones for our lead autoimmune pipeline candidate, Rezpegaldesleukin — which we also call REZPEG. Hitting those clinical development targets sets us up for significant data catalysts for REZPEG during 2025. Earlier in the year, we shared that enrollment had been completed for both of the Phase 2b trials Nektar is sponsoring. Our Resolve AD study in atopic dermatitis, which involves 400 patients, began enrolling in October 2023 and wrapped up enrollment after only 14 months. Our Resolve AA study in alopecia areata, with 90 patients, started in March 2024 and finished enrolling in about one year. Each of these studies was completed on schedule, even within highly competitive clinical trial environments for both indications — something I believe shows how enthusiastic patients and physicians are about REZPEG's novel mechanism of action and about the data generated so far. In a moment, J Z will go over some of the distinctive operational aspects of our studies that are intended to reduce clinical operational risk. We're eager to see data from both the atopic dermatitis and alopecia areata trials in Q2 and Q4 of this year, respectively. Now, within the U.S. by itself, more than 15 million individuals are living with moderate to severe atopic dermatitis. We're aware that fewer than 10% of the patients who could be given biologic treatments for this chronic skin condition are actually getting treated. Novel mechanisms are essential to expanding this underserved market. That same conviction applies to alopecia areata. Based on the National Alopecia Areata Foundation, close to 7 million people in the U.S. by itself have or will develop this disease, and a treatment market projected to reach $5.2 billion across the United States and Europe by 2023; this disorder has a major impact on patients' quality of life, and the approved JAK inhibitor therapies, given their high relapse rates, lack durability and may carry substantial potential safety risks. With REZPEG, our aim is to provide a more durable treatment option through a novel immunomodulating mechanism. Shifting to type 1 diabetes, we recently disclosed the clinical trial agreement with TrialNet, an international clinical trial network that leads diabetes research, under which they will run and pay for a Phase 2 clinical trial evaluating REZPEG in 66 patients with new-onset type 1 diabetes. We take pride in backing TrialNet's mission of pushing forward innovative mechanisms designed to slow or halt progression of this disease. Close to 2 million people in the U.S. have type 1 diabetes, and incidence of the disease keeps climbing at a rate of 3 to 5% each year. Brian will cover more on this later in the call. Now, regarding the progress we've achieved with our preclinical programs, during the past year we broadened the company's preclinical pipeline in immunology and inflammation. First, we keep advancing our novel TNF-R2 agonist antibody program, Nektar 0165. Work needed for an IND submission is still underway, with a target of filing during the latter half of 2025. At EULAR last year, we shared the initial preclinical findings, which showed this antibody produced a selective boost in Treg cell function. Because TNF-R2 agonism matters so much across various autoimmune conditions, Nektar 0165 might be developed for diseases like multiple sclerosis, ulcerative colitis, and vitiligo. A pipeline of bispecific molecules combining TNF-R2 agonism with other antibody targets is also being designed. Our plan is for the first bispecific in this program to reach readiness for IND-enabling studies during the next quarter but one. As these programs move forward, we anticipate sharing additional detail on our early pipeline, and Jay-Z will cover more on that afterward. Now, ahead of my R&D remarks, I'd like to welcome back Brian Kotzin, whose return to Nektar to head REZPEG development as Interim Chief Medical Officer we announced last month. Immunology expertise spanning more than 40 years belongs to Brian, along with broad experience in development and management. Since 2017 he has supported REZPEG's clinical development in multiple roles, and his deep familiarity with the program has made for a smooth transition. Before passing things to Brian, I'd like to emphasize that Nektar's financial position stays solid, with cash runway reaching into Q4 of 2026, and 2024 closing with $269 million in cash and investments available. I'll ask Brian to offer a few thoughts on his excitement about REZPEG, and to touch on our recent type 1 diabetes program announcement, before we hand things to Jay-Z for a fuller review of REZPEG's ongoing Phase 2b studies and our early pipeline programs. Brian?
Brian Kotzin
executiveThank you, Howard. Coming back to Nektar feels wonderful. As Howard pointed out, working on REZPEG has been a real privilege of mine since 2017, and after retiring in 2023 I even stayed on as a strategic advisor. So when Howard and Jay-Z reached out about the chance to rejoin my Nektar colleagues on this program, I was eager to jump in and assist. The promise of increasing regulatory T cells in autoimmune disease is something I care deeply about, and within this field REZPEG stands as the most advanced IL-2 Treg stimulating mechanism. After spending several years closely involved in its clinical development, my belief is that it could genuinely tackle unmet needs by providing safe and lasting therapeutic choices for patients fighting atopic dermatitis, alopecia areata, and now type 1 diabetes. As Howard noted, we just announced a collaboration agreement with TrialNet to assess REZPEG in a Phase 2 placebo-controlled clinical trial involving patients with new-onset type 1 diabetes. Ever since REZPEG first entered the clinic, I've been deeply interested in pursuing it for this indication, and teaming up with some of my TrialNet colleagues on this new clinical study has me thrilled. Among type 1 diabetes patients, an imbalance arises between regulatory T cells and pathogenic autoreactive T cells, causing the autoreactive T cells to wipe out insulin-producing beta cells within the pancreas. Research in mouse models along with early human studies of low-dose IL-2 and other agents have demonstrated that boosting Tregs may preserve insulin-producing beta cells. Preserving endogenous insulin secretion in this way is essential for better long-term health outcomes and quality of life among patients living with this disease. That's exactly why the work TrialNet is recommending for REZPEG has me so enthusiastic. Roughly 66 patients will be enrolled in the proposed placebo-controlled TrialNet study while they still retain partially preserved beta cell function and insulin production. Evaluation will begin with adult patients, then shift to pediatric and adult patients across different phases of the study. TrialNet aims to launch the study later this year. With that, I'd like to hand the call to JZ.
Jonathan Zalevsky
executiveThanks, Brian. It's great to be collaborating with you again on a day-to-day basis. As Howard said, back in January we shared that enrollment would be complete for the Resolve AD Phase 2b study in atopic dermatitis patients in a span of just under 14 months. Our thanks go out to the patients and physicians — their keen interest in this novel mechanism along with the proof-of-concept clinical data is what made finishing enrollment in this sizable Phase 2b trial possible. We're eager to share top-line results from the 16-week induction period this June. In February, the FDA handed REZPEG fast-track designation for treating adults and children with moderate to severe atopic dermatitis. That status lets us work hand in hand with the agency on shaping the registrational program for REZPEG, and we'll take advantage of it as we build our phase 3 registrational strategy in atopic dermatitis. A quick reminder: the Resolve AD trial randomized roughly 400 biologic naive patients with moderate to severe atopic dermatitis, split across three distinct REZPEG dosing regimens or placebo. With guidance from our scientific advisory board made up of top dermatologists in the field, we built this study to guarantee that high-quality sites were utilized and put criteria in place aimed at fixing certain operational execution problems seen in earlier trials. Participants came from about 110 sites around the world to guarantee sufficient geographic representation. Stratification of patients was done by geographic region and by baseline disease severity. 67% of patients were enrolled in Europe, spanning Poland, Bulgaria, Germany, Czechia, Spain, Croatia, and Hungary. 17% were enrolled in the U.S., while the remainder came from Canada and Australia. We aimed to keep U.S. recruitment balanced given the recent phenomenon over the last several years of a rising placebo effect seen in the U.S. We're quite happy with the final U.S. recruitment number of 17%, which sits closer to the recent successful atopic dermatitis studies when it comes to site distribution. Additional key criteria we applied in the trial include mandating that the majority of our sites be board-certified dermatologists or immunologists who had previously taken part in other atopic dermatitis studies. We also mandated that enrolled patients hit a strict EASI threshold that stayed consistent at both screening and randomization, which sets us apart from some other trials that have only needed EASI measurement at screening. By reconfirming that a patient's disease severity hasn't shifted meaningfully between screening and baseline, we can lower the chance of enrolling patients whose disease is flaring or episodic, patients with unstable disease, or those with a notable change between screening and randomization or screen test. Following randomization, patients get either REZPEG at 24 micrograms per kilogram twice a month, 24 micrograms per kilogram once a month, and 18 micrograms per kilogram twice a month, or placebo, over a 16-week induction treatment period. Once the induction phase is complete, patients who reach an EASI 50 or higher efficacy bar to move on from induction into maintenance are re-randomized into one of two maintenance treatment schedules at the same dose they started on, receiving that dose either monthly or every three months. The maintenance segment of this trial lasts 36 weeks, giving patients in the study a total of 52 weeks of treatment; after that 52-week treatment period ends, we continue following participants for one year, which lets us assess how REZPEG might deliver a long-term remittance effect. As I noted earlier, we anticipate top-line data from the 16-week induction portion of this Phase 2b trial in June, and we expect results from the study's 36-week maintenance period in Q1 of 2026. Now, moving to the Resolve AA study, alopecia areata is a skin condition where a patient's immune system wrongly targets the hair follicle and interferes with the body's usual capacity to retain and produce hair, resulting in hair loss. There's a solid rationale for REZPEG in this indication, grounded in how Tregs work to either stop or downregulate the disease's underlying pathology. Last month, we reported that enrollment had been completed for our 90-patient Phase 2b trial in alopecia areata. The trial enrolled patients at roughly 30 sites worldwide. To qualify for inclusion, patients needed to have severe to very severe disease, defined as SALT 50 to SALT 100 lasting at least six months. Enrollment broke down as 62% in Poland, 24% in Canada, and the remainder in the U.S. Those randomized will receive treatment for 36 weeks and be monitored for as long as 60 weeks overall. Our primary endpoint here is mean percent improvement in SALT, or the Severity of Alopecia Tool, at week 36; we'll also examine several other secondary endpoints, among them the share of patients seen to have differing levels of improvement in SALT score, which includes the regulatory approval endpoint SALT 20. We expect top-line data from the 36-week treatment period in Q4 of this year. Switching to our preclinical immunology programs, I'll begin with our novel TNF-R2 agonist antibody program, Nektar 0165. TNF-R2 agonism has been demonstrated to strengthen Treg function and help maintain Treg linear stability, particularly within the non-lymphatic tissue compartment. Genetic research indicates that when TNF-R2 is missing, the phenotypic outcome is autoimmunity along with other conditions resembling a FOXP3 loss of function. Conversely, when it's present and its signaling is activated, this has been linked to immune regulatory function and tissue protective effects. The first preclinical findings from this program, presented at EULAR last year, showed that Nektar 0165 has extremely high specificity for signaling via TNF-R2 on Tregs and boosting immunosuppressive activity. The data additionally demonstrated that the agonists identified by our team can signal via a single-arm monovalent antibody targeting the TNF-R2 multimeric receptor — a highly novel result for any TNF-R2 agonist antibody. Nektar 0165's distinctive and differentiated profile has us tremendously enthusiastic, and our belief is that it could emerge as a first-in-class therapy for a range of autoimmune conditions, among them multiple sclerosis, ulcerative colitis, and vitiligo; we're pushing this program toward the clinic at a rapid pace, with an IND submission planned during this year's second half. Because the TNF-R2 agonist antibody specificities our work uncovered function as single-arm antibodies, we've capitalized on that property to engineer a pipeline of bispecific molecules containing TNF-R2 that combine TNF-R2 agonism with additional specificities. Nektar 0166 is the name of the first such molecule. By harnessing several mechanisms, these assets yield innovative molecules aimed at autoimmune diseases; from this pipeline we intend to name our initial development candidate, Nektar 0166, in Q2 of this year, and we're eager to share further detail on that down the road. On the whole, interest has been building for a selective TNF-R2 agonist such as Nektar 0165, and as we proceed with IND-enabling studies and build out the bispecific pipeline, we stay receptive to chances to collaborate with parties who share interest in these spaces, mapping out the optimal route ahead. Prior to handing the call to Sandy, I want to offer a handful of remarks regarding Nektar 255, our oncology program built on IL-15.
Jonathan Zalevsky
executiveDuring the prior year, we shared findings regarding Nektar 255 demonstrating how it could potentially boost responses and outcomes for patients across many cancer therapies, in solid as well as liquid tumors. Research that appeared in Blood, a peer-reviewed journal from the American Society of Hematology, based on Stanford's IST, showed that when Nektar 255 was given alongside Stanford's CD19/CD22 bi-CAR T-cell therapy, it doubled the 12-month relapse-free survival rate among B-cell acute lymphoblastic leukemia patients, reaching 67% versus 38% for Stanford's historical controls who received that same CAR T-cell therapy. At ASH, we provided supporting evidence indicating Nektar 255 raised complete response rates after CD19-directed CAR T therapy among patients with relapse-refractory large B-cell lymphoma. Within the Nektar 255 treatment group, 73% attained a complete response at six months, whereas the placebo group saw 50%. This clinical benefit exceeds published historical benchmark data drawn from numerous pivotal trials and real-world meta-analyses involving currently available commercial CD19 CAR T-cell therapies. Lastly, interim data shared at SITC from Dr. Steven Lin's Phase 2 study indicates Nektar 255 may deliver clinical benefits for those with locally advanced non-small cell lung cancer. Findings reveal that Nektar 255, combined with durvalumab, produced a statistically significant gain in the eight-week absolute lymphocyte count relative to historical control data. Such results reinforce our confidence in Nektar 255's therapeutic potential as a novel use in combination treatment alongside checkpoint inhibitors. The expanding evidence base demonstrates its broad applicability for combining with many therapies across cancer indications. Going forward, we will keep collaborating with AbelZeta to assess Nektar 255 alongside their tumor-infiltrating lymphocytes in advanced non-small cell lung cancer patients who fail to respond to anti-PD-1 therapy. We remain engaged with Merck KGaA to assess Nektar 255 together with Bavencio in their Phase 2 Javelin Bladder Medley study, where the first possible PFS readout is anticipated around the middle of this year, given that this analysis is event-driven. While we keep producing supportive data through these combination studies, we also keep investigating the optimal areas for ongoing development of this drug candidate alongside our collaborators. With that, I'll hand the call over to Sandy for a review of our financial guidance.
Sandra Gardiner
executiveThanks, JZ, and good afternoon to all of you. We closed out 2024 holding $269.1 million in cash and investments, and our balance sheet carries no debt. On December 2, 2024, we finished the divestiture of our Huntsville manufacturing facility, receiving $64.7 million in cash after transaction costs, plus an equity stake of roughly 20% in the newly formed portfolio company, Gannett BioChem. Moving to the income statement, revenue came in at $29.2 million for Q4 of 2024 and $98.4 million across the full year 2024. R&D expenses totaled $28.7 million in Q4 and $120.9 million for the full year. G&A expenses came to $17.1 million in Q4 and $76.8 million for the full year. Related to the divestiture of our Huntsville manufacturing facility, we recorded a gain of $40.4 million. Non-cash interest expense was $10.2 million in Q4 and $28.1 million for the full year. Net income in Q4 reached $7.3 million, or $0.03 basic and diluted earnings per share. Across the full year 2024, net loss totaled $119 million, or $0.58 basic and diluted loss per share. Now I'll walk through our 2025 financial guidance. Our financial position remains strong, and we still anticipate our cash runway extending into Q4 of 2026. We intend to finish 2025 with roughly $100 million in cash and investments. Full-year 2025 revenue is projected at between $40 million-$50 million, largely consisting of non-cash royalties. Because of the divestiture of our Huntsville manufacturing facility, product revenue and cost of goods sold will no longer apply to us. We project full-year R&D expense in the range of $110 million-$120 million, which includes around $5 million-$10 million of non-cash depreciation and stock-based compensation expense. R&D expense should stay in line with 2024 levels as we advance our Phase 2b studies in atopic dermatitis and alopecia areata; full-year 2025 G&A expense is expected to land between $60 million and $65 million, including approximately $5 million-$10 million of non-cash depreciation and stock-based compensation expense. Full-year non-cash interest expense is projected at between $15 million-$20 million. As I mentioned before, we expect to close the year with approximately $100 million in cash and investments. With that, we'll now open the call for questions. Operator?
Yasmeen Rahimi
analystAfternoon, everyone, and thanks so much for the wonderful updates — we’re really eager to see the data from both studies this year. I suppose my first question is this: you’ve demonstrated truly remarkable dose responses in the EASI scores at an earlier stage. We’d like to hear how you’re approaching dose response among the three dose arms. And second, could you perhaps remind us what the criteria or responder analysis is that determines whether patients are eligible to move from the induction phase into the maintenance phase? I’ll get back in the queue.
Howard Robin
executiveJZ, do you want to handle that one? Does that address the question?
Jonathan Zalevsky
executiveOkay, yes, thank you, Yas. Regarding that initial question on dose response: we covered it using three separate cohorts, which looked at both the amount of the dose and how often it was given. Two of those cohorts tested 24 micrograms per kilogram. One of them gave that amount two times per month, while the other gave it one time per month. The reason we altered the schedule was that it was meant to mirror the pharmacodynamic profile of the Tregs we measure in blood. That's why we wanted an identical Cmax on a single occasion, with differing exposures in the monthly versus twice-monthly setting. That was the aim, to evaluate it using PK/PD understanding. We additionally picked 18 micrograms per kilogram given two times per month. That amount is above the 12 micrograms per kilogram we had used in the Phase 1B study. Our view was that 12, although it did show a small separation from placebo, leaned toward the weaker end on efficacy. We wanted to test a dose above 12 micrograms per kilogram in the Phase 2b. So we went with 18 micrograms per kilogram, which sits midway between 12 and 24 from the Phase 1B study. Those are our expectations regarding how the Phase 2b was designed. As for the rules for patients transitioning from induction into the maintenance arms of the study: after the 16-week inductions finish, those with an EASI 50 response or better qualify for re-randomization into maintenance. Once in maintenance, they get re-randomized to continue at the same dose level they had during induction. However, the schedule now becomes either one time per month or one time every three months. We apply that EASI 50 threshold for moving from induction into maintenance.
Yasmeen Rahimi
analystThanks, JZ.
Julian Harrison
analystHello, and I appreciate you taking my questions. To start, regarding the Phase 2b atopic dermatitis results we expect in the next quarter, could you discuss what level of efficacy, whether measured by EASI or IGA, you would view as commercially viable and worth moving REZPEG into pivotal development?
Howard Robin
executiveYes, that is a solid question. I believe we have invested considerable effort in that space, particularly given that Amgen has just disclosed its OX-40 data. I will have JZ provide you with a more comprehensive response on that.
Jonathan Zalevsky
executiveYes, thank you, Julian. We are clearly observing at least 2 distinct patterns of activity. Naturally, there exist EASI ranges that are active and that one would want to reach. Beyond that, the split from placebo matters greatly—both of those elements count a lot. We are pleased with what our Phase 1B trial revealed, correct, since it demonstrated a striking placebo-adjusted divergence as well as an 83% improvement relative to baseline. Our aim is to reproduce that type of result in the Phase 2b. We also recognize that for a medication with a novel mechanism and one that has already displayed a remissive effect, as demonstrated in the Phase 1B, even efficacy at the level of Dupixent, which is the current standard of care, would represent a highly successful result for us. We are certainly mindful of the latest findings in this area, such as Amgen's ROCKET data. In my view, that data is likely regarded as somewhat underwhelming by certain individuals who have discussed and reviewed it. We believe we are well positioned to reproduce the Phase 1B findings we obtained in that regard. Keep in mind that this is not a zero-sum game. This truly is a substantially underserved market involving a very serious illness. A novel mechanism will surely be valued by patients and physicians—of that I am certain.
Julian Harrison
analystUnderstood. Thanks. That clarifies things well. If I could ask one more. With the litifilimab royalty monetization that happened recently, I'm wondering how you view your Dupixent rights. Is there anything about litifilimab that stands apart in a way we should flag?
Howard Robin
executiveJZ, do you want to speak to that?
Jonathan Zalevsky
executiveSure. Naturally, the ways these drugs work differ, correct? For one, there’s the BDCA2 inhibitor, which goes after the plasmacytoid side more; and naturally, that medication has demonstrated effects in systemic lupus as well as cutaneous lupus. It appears that it may hold even greater promise for the skin-related version of the illness, while Dapi, correct, is an agent aimed at CD40 ligand, right? It tackles distinct mechanisms of action. From a mechanistic standpoint, I believe both medications have shown striking Phase 2 outcomes. Clearly, Dapi also has favorable phase 3 results.
Julian Harrison
analystOkay. That's great, thanks.
Jay Olson
analystHi there, congratulations on the momentum, and I appreciate this update. Perhaps one more top-line question—when Q2 brings the Phase 2 atopic dermatitis data, could you describe how much data you intend to include in that top-line announcement and which secondary endpoints might be worth watching? And what kind of profile do you believe would let you take meaningful share in a first-line setting?
Howard Robin
executiveYes, those are good questions. Up to now, we've said very little about the specific secondary endpoints. Obviously, given that this is a novel mechanism and an entirely different approach from IL-13, what I'd want is a drug whose activity resembles Dupixent's but with a biologic profile that's very distinct. I'll have JZ expand on that. JZ, go ahead.
Jonathan Zalevsky
executiveOkay, absolutely. Thanks, Jay. So, to restate what I mentioned earlier, we haven't provided guidance regarding the specific top-line figure. Naturally, most of the information we'd need to share at a medical conference, our plan is to concentrate, clearly, on the 16-week induction results, just as we've outlined, and to provide at least a minimal directional sense, correct, of how the drug is performing. That, I believe, is the absolute minimum. We can address that further at a later point. Regarding the profile, I mean, it's fairly evident that the most effective route to affecting share within the front-line setting comes through efficacy, correct? Should we manage to reproduce the Phase 1B findings, which were truly quite pronounced, quite remarkable, clearly, that stands as among the most powerful means of influencing the first-line treatment space. Beyond all of that, our mechanism is entirely distinct. We aren't another IL-13; we aren't a depleting antibody in the way RocA is. What we're actually offering is an entirely separate mechanism of action. We're offering the data set that has already shown the capability for truly sustained responses, which might convert into a dosing schedule at a very, very low frequency, which would, at the very least, prove extremely convenient for patients. We believe there are genuinely multiple paths through which we can affect this market. We're quite thrilled that, as a novel Treg mechanism, we gain these extra avenues to do so.
Howard Robin
executiveIt's also worth noting, I believe, that although Dupixent is clearly a very good drug — there's no argument about that — a substantial share of patients eventually stop responding to Dupixent treatment. As JZ mentioned a moment ago, this market really needs a new mechanism that functions in an entirely distinct manner. Whenever we end up putting our data side by side with the Dupixent data, of course I'd hope to find parallels, but keep in mind that what you're looking at is an entirely different approach to treating this condition.
Jay Olson
analystThanks. That's really useful. If I may squeeze in something about 255, could you share whatever's new regarding when we might get the interim PFS data from the Javelin Bladder Medley trial, and what specifically we ought to be watching for? Thanks.
Howard Robin
executiveThat readout ought to arrive around the middle of this year. JZ, would you like to add anything else?
Jonathan Zalevsky
executiveCorrect. It really does depend on events, doesn't it? You have to wait for PFS events to build up. Back around the midpoint of the year, Merck provided some direction, suggesting that summer was roughly when those might start showing up. When it comes to PFS events, naturally we're aiming to do better on PFS and perhaps even on OS compared with single-agent Bavencio in this setting — that is, after chemotherapy. That's clearly what the trial is trying to achieve. That's the outcome we're hoping for. It's also the outcome Merck is hoping for. I mean, that's the way this trial was set up, using Bavencio as an active comparator so we can directly evaluate the combination of 255 plus Bavencio against Bavencio by itself.
Jay Olson
analystThanks, that's really useful, and I appreciate you taking the questions.
Roger Song
analystThanks for the update, and for taking our questions as well. I've got one quick item about the Phase 2 atopic dermatitis study. Considering how many patients you've now enrolled relative to that recent atopic dermatitis trial, what do you expect the patient baseline to look like? What are your expectations on that front? Thank you.
Howard Robin
executiveJZ or Brian, would either of you like to handle that?
Jonathan Zalevsky
executiveYes, of course. Appreciate it, Roger. A key thing we're hoping to observe is a baseline EASI sitting somewhere around 25 to 30, correct? The reason is that, looking at prior trials over the years, those sorts of baseline EASI values across the whole population have typically correlated with reduced placebo responses overall, plus stronger trials. When patients start out with elevated EASI scores, there's a wider dynamic range available for measurement. That's something we'd love to see in this trial — a baseline falling in roughly that zone. As far as what to expect for placebo, honestly, we have no way of knowing. It's a blinded trial, after all. Naturally, we're hoping for placebo response rates that are far, far smaller than what's been documented lately in certain trials, among them those from last December, for instance the ones from Q32, where the placebo rate came in extremely high. Something I attempted to touch on earlier during this call is that we deliberately incorporated several prospective elements into our trial, for example restricting our geographic footprint within the U.S. Just 17% of our sites were located in the U.S., and we concentrated on board-certified dermatologists and immunologists who had proven experience conducting atopic dermatitis trials, and we also measured EASI scores repeatedly prior to drug administration and patient randomization. We put all of that in place ahead of time to safeguard the trial and make sure that, ideally, we avoid an extremely elevated placebo response rate. Of course, once we share the top line results later this year in June, we'll reveal exactly what that figure turns out to be. Thanks for asking, Roger.
Roger Song
analystThanks.
Mayank Mamtani
analystHello there, Dean, and good afternoon. We appreciate you fielding our questions. It's encouraging to witness the advancement you've made. Would you be able to speak to something connected to what was just mentioned, JZ? Is there anything you can share regarding the rate of screen failures you've observed under the particularly rigorous standards you're applying, and how that might stack up against other trials that have examined screening followed by randomization? I have one brief follow-up.
Jonathan Zalevsky
executiveYes, that's the sort of detail we'd likely provide down the road, at the point when we unveil what the study found.
Mayank Mamtani
analystAll right, all right, understood. And after that, regarding the escape arm component within the protocol, in what manner do patients enter the escape arm — could you quickly walk me through how that is roughly organized for induction as well as maintenance? And finally, just at a broad level, the read-through from the AD data set over to the Resolve A study — any translational markers you happen to be examining would be useful to hear about. Thanks for taking our question.
Jonathan Zalevsky
executiveAlright. Yeah, so according to how the trial is structured — this was also among the specialist recommendations the steering committee provided to us — once a patient completes those sixteen weeks of induction, should their condition not improve beyond EASI 50, they may choose to join an escape arm. That escape arm consists of the 24 microgram per kilogram Rezpegaldesleukin dose administered two times per month, which is especially beneficial for patients, say, in a blinded study who might have been assigned to a placebo group, correct? It provides everybody an opportunity to obtain the drug. That's how the escape arm functions. The main entry point occurs at that sixteen-week mark, at induction's conclusion, for those patients who don't achieve the EASI 50 or superior rerandomization threshold needed to move into maintenance. A second route by which patients can join the escape arm is while in maintenance, should they, for whatever reason, experience a loss of activity or a loss of response, giving them another opportunity to enter that escape arm. That's essentially how it operates. Offering an escape arm therapy to trial participants is quite standard for studies of this type. Regarding the other sorts of questions you raised about read-through, well, we chose alopecia primarily because it's a major dermatological indication, correct? As you're aware, with REZPEG, we have observed activity across several dermatological inflammatory conditions, spanning skin manifestations of lupus, psoriasis, and atopic dermatitis. Plus there's the fundamental understanding regarding immune privilege biology and the part Tregs play in assisting to preserve and uphold that immune privilege state. We'll be examining biomarkers in both studies. As you observed from our Nature Communications publication back in October of last year, quite a few biomarkers we assess are induction markers, since our drug functions as an agonist. I anticipate we can measure those induced pathways regardless of the patient's underlying disease etiology. Those will simply reflect the signaling of our molecule onto Tregs, for instance. Those are going to be some highly significant correlative biomarkers that we will gather going forward. We look forward to the readout from both of these studies. As we talked about, the first one, atopic derm, arrives in June for that induction. For alopecia areata during Q4 of this year, we anticipate reading out the 36-week treatment data from that trial too.
Mayank Mamtani
analystThanks, JZ.
Arthur He
analystHi there. Good afternoon, Howard and the rest of the team. Appreciate you fielding our question. JZ, thank you for the extra detail regarding the dose regimen in the AD study. I'd like to dig a bit deeper into the reasoning behind selecting those 3 regimen arms. What's the reason for not choosing a dosing regimen higher than 24 micrograms per kilogram Q2W? Right. I also had another question about the trial.
Jonathan Zalevsky
executiveYes. Throughout the clinical program, we've looked at a range of doses, including weight-based dosing, like the kind we're applying in this study, as well as flat dosing, which was used in other trials such as the lupus study. When you consider it, that provides a spectrum of differing doses that we have set. We've tested levels much higher and much lower. In fact, 24 micrograms per kilogram is truly an optimal dose level. It delivers everything we're looking for in terms of a PK/PD relationship. We bind the target quite effectively. We achieve very strong Treg expansion. At that dose level, you're able to dose for an extremely long period without observing any cessation or hysteresis in any pharmacodynamic responses. Based on the biomarker data requested earlier, which we published, you can likewise observe a very strong induction of immune pathways at that dose level. That truly is an optimal dose level, and it's the one we're really concentrating on.
Arthur He
analystThank you for taking that. My next question concerns, I think, both AD as well as the AA study. Would you remind us what the stratification looks like in each?
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.